Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | RIN1 | Q13671 | 1/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.65 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | SHBG | P04278 | 3/20 | 0.65 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.65 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.65 |
| ▸ | G6PD | P11413 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.65 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7062423 | 1.00 | ABL1 (1.00) | ABL1RIN1GPBAR1LMNACYP3A4 | |
| SCHEMBL4339194 | 1.00 | ABL1 (1.00) | ABL1RIN1GPBAR1LMNACYP3A4 | |
| SCHEMBL2509859 | 1.00 | ABL1 (1.00) | ABL1RIN1GPBAR1LMNACYP3A4 | |
| SCHEMBL12057060 | 1.00 | ABL1 (1.00) | ABL1RIN1GPBAR1LMNACYP3A4 | |
| SCHEMBL2509858 | 1.00 | ABL1 (1.00) | ABL1RIN1GPBAR1LMNACYP3A4 | |
| SCHEMBL5445469 | 0.83 | ABL1 (0.70) | ABL1RIN1GPBAR1LMNACYP3A4 | |
| SCHEMBL1115615 | 0.83 | ABL1 (0.70) | ABL1RIN1GPBAR1LMNACYP3A4 | |
| SCHEMBL6881931 | 0.83 | ABL1 (0.70) | ABL1RIN1GPBAR1LMNACYP3A4 | |
| SCHEMBL6448971 | 0.83 | ABL1 (0.70) | ABL1RIN1GPBAR1LMNACYP3A4 | |
| SCHEMBL6876271 | 0.83 | ABL1 (0.70) | ABL1RIN1GPBAR1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| EP-2004669-A1 | AZAHETEROCYCLYL DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2008-12-24 | — | — | EP | disclosed |
| EP-2004668-A2 | AMINO DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2008-12-24 | — | — | EP | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
| WO-2007118830-A1 | AZAHETEROCYCLYL DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007118832-A2 | AMINO DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | ABL1 992/4885RIN1 4338/4885GPBAR1 589/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | ABL1 310/4885RIN1 4331/4885GPBAR1 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.